Cargando…

Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis

OBJECTIVE: To identify risk factors for haemorrhagic transformation in Chinese patients with acute ischaemic stroke treated with recombinant tissue plasminogen activator. METHODS: We searched electronic databases including PubMed, EMBASE, CNKI and WanFang Data for studies reporting risk factors of h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Yijia, Yang, Yaqiong, Zhou, Muke, He, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312075/ https://www.ncbi.nlm.nih.gov/pubmed/30637125 http://dx.doi.org/10.1136/svn-2018-000141

Ejemplares similares

Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous thrombolysis: A meta-analysis
por: Wen, Lihong, et al.
Publicado: (2020)

Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis
por: You, Shoujiang, et al.
Publicado: (2018)

A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischaemic stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis
por: Wardlaw, Joanna M, et al.
Publicado: (2012)

Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
por: Chenna, Vijay, et al.
Publicado: (2018)

Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review
por: Wang, Xia, et al.
Publicado: (2018)

Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
por: Dong, Yi, et al.
Publicado: (2016)

Haemorrhagic transformation following ischaemic stroke: A retrospective study
por: Pande, S. D., et al.
Publicado: (2020)

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
por: Ong, Cheung-Ter, et al.
Publicado: (2017)

Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers
por: Aparicio, Hugo J., et al.
Publicado: (2015)

Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study
por: Sadeghi-Hokmabadi, Elyar, et al.
Publicado: (2016)

Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18–64 years in the USA
por: Joo, Heesoo, et al.
Publicado: (2016)

Absolute blood eosinophil count could be a potential biomarker for predicting haemorrhagic transformation after intravenous thrombolysis for acute ischaemic stroke
por: Jucevičiūtė, Neringa, et al.
Publicado: (2019)

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Publicado: (2012)

Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population
por: Guo, Yutao, et al.
Publicado: (2016)

Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator
por: Shimada, Yoshiaki, et al.
Publicado: (2018)

Ischaemic stroke and the recanalization drug tissue plasminogen activator interfere with antibacterial phagocyte function
por: Vogelgesang, Antje, et al.
Publicado: (2017)

Mechanical thrombectomy in acute ischaemic stroke patients with pre-interventional intracranial haemorrhage following intravenous thrombolysis
por: Styczen, Hanna, et al.
Publicado: (2021)

Cost-effectiveness of recombinant tissue-type plasminogen activator for acute ischaemic stroke with unknown time of onset: a Markov modelling analysis from the Chinese and US perspectives
por: Zhao, Songfeng, et al.
Publicado: (2022)

The Chinese Stroke Association scientific statement: intravenous thrombolysis in acute ischaemic stroke
por: Dong, Qiang, et al.
Publicado: (2017)

Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in a Patient with Acute Ischemic Stroke Secondary to Aortic Dissection
por: Hong, Keun-Sik, et al.
Publicado: (2009)

Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke
por: Chapman, Sherita N, et al.
Publicado: (2014)

Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke can Cause Inferior Myocardial Infarction?
por: Almasi, Mostafa, et al.
Publicado: (2016)

Carotid Artery Stenting for Acute Ischemic Stroke Patients after Intravenous Recombinant Tissue Plasminogen Activator Treatment
por: Deguchi, Ichiro, et al.
Publicado: (2016)

Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke
por: Joo, Heesoo, et al.
Publicado: (2017)

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients over 80 Years Old: The Fukuoka Stroke Registry
por: Matsuo, Ryu, et al.
Publicado: (2014)

Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome
por: Kounis, Nicholas G., et al.
Publicado: (2011)

Haemorrhagic Transformation after Ischaemic Stroke in Patients Taking Non-vitamin K Antagonist Oral Anticoagulants
por: Purrucker, Jan C., et al.
Publicado: (2017)

Association between non-high-density lipoprotein cholesterol and haemorrhagic transformation in patients with acute ischaemic stroke
por: Wang, Yanan, et al.
Publicado: (2020)

Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
por: Choi, Joon-Ho, et al.
Publicado: (2016)

The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy
por: Shibata, Soichiro, et al.
Publicado: (2022)

Systemic innate myeloid responses to acute ischaemic and haemorrhagic stroke
por: Stephens, Ruth, et al.
Publicado: (2022)

Evaluation of Cerebral Perfusion in Patients Undergoing Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis
por: HIRANO, Teruyuki
Publicado: (2015)

Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke
por: Yoneda, Yukihiro, et al.
Publicado: (2009)

Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review
por: Bhatt, Archit, et al.
Publicado: (2013)

Intravenous Tissue Plasminogen Activator for an Ischemic Stroke with Occult Double Primary Cancer
por: Yoneda, Yukihiro, et al.
Publicado: (2014)

Efficacy of Urinary Kallidinogenase Plus Intravenous Recombinant Tissue Plasminogen Activator for Stroke Patients With Extended Window: A Retrospective Analysis
por: Li, Xueyuan, et al.
Publicado: (2023)

Key CT markers for predicting haemorrhagic transformation after ischaemic stroke: a prospective cohort study in China
por: Wei, Chenchen, et al.
Publicado: (2023)

A Canine Model of Hemorrhagic Transformation Using Recombinant Tissue Plasminogen Activator Administration After Acute Ischemic Stroke
por: Jiang, Run-Hao, et al.
Publicado: (2019)

Comparison of Effectiveness and Safety of Low-Dose Versus Standard-Dose Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke: A Meta-Analysis
por: Karedath, Jithin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lmd7iu0r92c3d1145vkpkvo9uv